True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study by Mariathas, M et al.
Confidential: For Review Only
Is the Current Threshold for Diagnosis of “Abnormality”, 
including Non ST Elevation Myocardial Infarction, using 
 Raised High Sensitivity Troponin Appropriate for a Hospital 
Population?  The CHARIOT Study 
Journal: BMJ
Manuscript ID BMJ.2018.046867.R1
Article Type: Research
BMJ Journal: BMJ
Date Submitted by the 
Author: 18-Dec-2018
Complete List of Authors: Mariathas, Mark; University Hospital Southampton NHS Foundation 
Trust, Cardiology
Allan, Rick; University Hospital Southampton NHS Foundation Trust, 
Cardiology
Ramamoorthy, Sanjay; University Hospital Southampton NHS 
Foundation Trust, Emergency Medicine
Olechowski, Bartosz; University Hospital Southampton NHS Foundation 
Trust, Cardiology
Hinton, Jonathan; University Hospital Southampton NHS Foundation 
Trust, Cardiology
Azor, Martin; University Hospital Southampton NHS Foundation Trust, 
Coding
Nicholas, Zoe; University Hospital Southampton NHS Foundation Trust, 
Cardiology
Calver, Alison; University Hospital Southampton NHS Foundation Trust, 
Cardiology
Corbett, Simon; University Hospital Southampton NHS Foundation Trust, 
Cardiology
Mahmoudi, Michael; University Hospital Southampton NHS Foundation 
Trust, Cardiology
Rawlins, John; University Hospital Southampton NHS Foundation Trust, 
Cardiology
Simpson, Iain; Southampton General Hospital, Cardiovascular & 
Thoracic, Southampton
Wilkinson, James; University Hospital Southampton NHS Foundation 
Trust, Cardiology
Kwok, Chun Shing; Keele University, Institute for Science & Technology 
in Medicine
Cook, Paul; University Hospital Southampton, Clinical Biochemistry
Mamas, Mamas; Keele University, Institute for Science & Technology in 
Medicine
Curzen, Nick; University Hospital Southampton NHS Foundation Trust, 
Cardiology
https://mc.manuscriptcentral.com/bmj
BMJ
Confidential: For Review Only
Keywords: High sensitivity troponin, 99th percentile, Hospital population
 
Page 1 of 56
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
REVISED MANUSCRIPT
Mariathas et al
The CHARIOT Study
December ‘18
1
Is the Current Threshold for Diagnosis of “Abnormality”, including Non-ST 
Elevation Myocardial Infarction, using Raised High Sensitivity Troponin 
Appropriate for a Hospital Population? 
The CHARIOT Study
Mark Mariathas1,2 BM BSc, Rick Allan3,  Sanjay Ramamoorthy4 MA MBBS,  Bartosz Olechowski1,2 MD, 
Jonathan Hinton1,2 BM,  Martin Azor5,  Zoe Nicholas1 BSc,  Alison Calver1 MBBS MD,  Simon Corbett1 
MBBS PhD,  Michael Mahmoudi1,2  MBBS, PhD,   John Rawlins1  MBBS  MD,  Iain Simpson1 MB ChB 
MD, James Wilkinson1 MBBS PhD,  Chun Shing Kwok6 MBBS BSc,  Paul Cook MBBS3, PhD,  Mamas A. 
Mamas6, BM BCh, MA, DPhil,  Nick Curzen1,2  BM(Hons), PhD *
1Coronary Research Group, University Hospital Southampton NHS Foundation Trust 
2Faculty of Medicine, University of Southampton, Southampton, UK
3Department of Biochemistry, University Hospital Southampton NHS Foundation Trust
4Emergency Department, University Hospital Southampton NHS Foundation Trust
5Coding Department, University Hospital Southampton NHS Foundation Trust
6Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and 
Health Sciences, Keele University, Stoke-on-Trent, UK.
Keywords
High sensitivity troponin, 99th percentile, hospital population
Word Count 3541
Funding:  Unrestricted Research Grant – Beckman Coulter
Page 2 of 56
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
REVISED MANUSCRIPT
Mariathas et al
The CHARIOT Study
December ‘18
2
*corresponding author
Prof.  N Curzen BM(Hons) PhD FRCP
Professor of Interventional Cardiology
E Level North Wing
University H spital Southampton NHS Trust
Tremona Road
Southampton SO16 6YD
UK
+442381204972
nick.curzen@uhs.nhs.uk
Competing interests:
M. Mariathas – none declared
R. Allan – none declared
B. Olechowski – none declared
S. Ramamoorthy – none declared
M. Azor – none declared
Z. Nicholas – none declared
A. Calver – none declared
S. Corbett – none declared
M. Mahmoudi – none declared
J. Rawlins – none declared
I. Simpson – none declared
J. Wilkinson – none declared
C.  Kwok- none declared
M. Mamas- none declared 
P. Cook – none declared
N. Curzen – unrestricted research grants from: Boston Scientific; Haemonetics; Heartflow; Beckmann 
Coulter. Speaker fees/consultancy from: Haemonetics, Abbot Vascular; Heartflow; Boston Scientific. 
Travel sponsorship – Biosensors, Abbot, Lilly/D-S; St Jude Medical, Medtronic.
All authors take responsibility for all aspects of the reliability and freedom from bias of the data 
presented and their discussed interpretation.
Page 3 of 56
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
REVISED MANUSCRIPT
Mariathas et al
The CHARIOT Study
December ‘18
3
Abstract
Objective
Clinicians use the cardiac troponin (cTn) assay to aid in the diagnosis of an acute myocardial infarction 
(AMI).  Each assay manufacturer  provides the 99th percentile for cTn levels in a group of healthy 
individuals, and this level is taken as the upper limit of normal (ULN). The objective of this study was 
to determine the distribution, and specifically the true 99th percentile, for the whole hospital 
population, using the cTn assay currently employed routinely at our institution. 
Design
Prospective study of 20,000 consecutive patients undergoing blood sampling for any reason at a large 
teaching hospital. Hs-cTnI concentrations (Beckman Coulter Access AccuTnI+3 assay) were nested for 
analysis in all cases except those in whom the supervising physician had requested hs-cTnI for clinical 
reasons.
Setting
University Hospital Southampton NHS Trust (UHS).
Participants
20,000 consecutive individuals, inpatient or outpatient, undergoing blood tests at UHS for any clinical 
reason. 
Main outcome measures
Distribution of hs-cTnI concentrations of all study patients, and specifically the 99th percentile.
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Results
The 99th percentile of hs-cTnI for the whole population (n=20,000) was 296 ng/L, compared to a 
manufacturer quoted 99th percentile of 40 ng/L (currently used clinically as the ULN). In 1 in 20 (5.4%, 
n=1080) of the total population hs-cTnI concentrations were above 40 ng/L. After exclusion of 
individuals diagnosed with an acute myocardial infarction (AMI) (n=122), or those in whom troponin 
was requested (n=1707), the 99th percentile for the remainder (n=18,171) was 189 ng/L. The 99th 
percentile for inpatients (n=4759) and outpatients (n=9280) was 563 ng/L and 65 ng/L, respectively. 
Patients from the emergency department (n=3706) had a 99th percentile of 215 ng/L, with 6.1% 
(n=225) above the quoted ULN. 39.02% (n=48) of all individuals from the critical care units (n=123) 
and 14.16% (n=67) of all medical inpatients had a hs-cTnI concentration above the quoted ULN. 
Conclusions
In 20,000 consecutive patients undergoing a blood test for any reason at this hospital 1 in 20 have a 
hs-cTnI above the supplied ULN. These data highlight the need for clinical staff to interpret hs-cTnI 
concentrations carefully, particularly when applying the supplied ULN to diagnose AMI. The use of hs-
cTnI to diagnose AMI in any patient could lead to misdiagnosis in the absence of an appropriate clinical 
presentation.
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Introduction
The use of increasingly sensitive troponin assays for the exclusion or diagnosis of acute myocardial 
infarction (AMI) has become universal. The diagnosis of AMI is now defined by a rise and/or fall of 
cardiac troponin (cTn) concentration, now the gold standard biomarker(1), with at least one value 
above the 99th percentile derived from a reference population of healthy individuals in the context of 
an appropriate clinical presentation (3-5). 
Under most circumstances, the troponin assay is requested by front line clinical staff to determine 
whether or not a patient is experiencing a Type 1 myocardial infarction (T1MI), which is due to 
coronary plaque rupture or erosion, since robust evidence has demonstrated symptomatic and 
prognostic benefit from the application of early pharmacological and interventional treatment 
strategies in such patients. However, particularly with the advent of newer assays, this strategy has 2 
potential challenges.
Firstly, elevated  cTn concentrations, particularly in patients not presenting with a typical history of 
cardiac pain, are often due to myocardial injury or Type 2 myocardial infarction (T2MI)(6, 7), which is 
secondary to ischaemia due to either increased oxygen demand or decreased supply rather than a 
plaque erosion event (8-10). This is not well recognized when the troponin test is requested, or the 
result interpreted, and is especially important because the majority of patients with T2MI have not 
been shown to benefit from the same aggressive pharmacotherapy and invasive investigation and 
treatment that is offered as standard in cases of T1MI(11), with some exceptions including 
spontaneous coronary dissection, coronary embolism and coronary spasm (10, 12). In fact, such 
misinterpretation may lead to inappropriate management, including prolonged antiplatelet therapy 
and invasive coronary angiography, with or without revascularization.
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Secondly, the assay-specific 99th centile (ULN) is generally applied as a binary “rule in” or “rule out” 
threshold for AMI. Whilst recent trial data confirm the veracity of the use of early cTn concentrations 
to confidently exclude the diagnosis of AMI (13-16), the assumption that a concentration above that 
level implies AMI (and in particular a T1MI) is often inappropriate. Both of these potential issues may 
be compounded in clinical practice by the increasing sensitivity of the available assays that are able to 
detect troponin at much lower concentrations than previously (5). Consequently, new highly sensitive 
cardiac troponin (hs-cTn) assays (17-21) allow for rapid exclusion of AMI, and thereby facilitate the 
early discharge of patients from hospital. Furthermore, modern hs-cTn assays can detect troponin in 
more than 50% of the general population, with some assays able to detect troponin in everyone(22). 
The appropriate interpretation of the “elevated” hs-cTn, particularly in relation to the diagnosis of 
T1MI, is therefore dependent upon a clinical presentation consistent with this diagnosis, and in 
particular, a history of cardiac-sounding chest pain, according to the guidelines. 
The International Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical 
Applications of Bio-Markers (IFCC TF-CB) currently recommends that the 99th percentile for any assay 
can be calculated using  300 ‘healthy’ men and 300 ‘healthy’ women(23). Given the number of factors 
that are well known to affect an individual’s troponin (23), including age(24), gender(25), glomerular 
filtration rate(26), left ventricular function(27), and the presence of significant inflammatory 
conditions (28), the appropriateness  of the clinically applied concept of an ULN for the hs-cTn assay 
requires closer scrutiny, particularly when it was derived from a limited number of healthy individuals. 
Importantly, the approaches to determining the supplied 99th percentile are also variable (29-31).
The aims of this study were to determine (a) the true distribution of hs-cTnI concentration in an 
unselected all comer hospital population, both inpatient and outpatient, and, more specifically, (b) 
the 99th percentile for this population using 20,000 consecutive patients. Our hypothesis was that the 
true distribution of hs-cTnI in this population would differ from the supplied ULN for this assay, 
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thereby highlighting the potential for misinterpretation of a value above this level in routine clinical 
practice, particularly the validity of applying the latter as the binary arbiter of the diagnosis of AMI, 
especially T1MI. 
Methods
Study population
This was a prospective, observational study that included 20,000 consecutive patients aged at least 
18 years in whom a biochemistry blood investigation was requested for clinical reasons determined 
by their supervising physician at our institution, a large University teaching hospital in the United 
Kingdom. Patients were included regardless of the setting in which the blood test was requested, so 
that the study population included outpatients and inpatients, emergency department attendees, 
elective and emergency admissions, and every specialty within the hospital. For each patient included 
in the study only one troponin measurement was performed on the first biochemistry blood sample 
that became available during the study period. That individual was then excluded from further 
sampling, in order that a consecutive series of 20,000 different patients were included. For some of 
the study analysis, patients who were discharged from hospital with a diagnosis of AMI or in whom a 
hs-cTnI level was requested by the clinical team, which was determined through a review of the 
electronic blood request forms submitted to the biochemistry department and via electronic 
discharge summaries, were excluded. 
Ethics & Regulatory Approval
This research project was undertaken according to the principles of Good Clinical Practice and the 
Declaration of Helsinki.  The study was approved by the local ethical committee who then referred it 
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to the Health Research Authority (HRA) UK and its independent Confidentiality Advisory Group (CAG) 
for further approval (Rec reference: 17/SC/0042, IRAS project ID: 215262). The CAG approval was 
required based upon 2 unusual aspects of the methodology. Firstly, the method did not require 
knowledge or consent from patients that an extra blood assay was being performed. Secondly, apart 
from those in whom a hs-cTnI was requested as part of their routine clinical care by their supervising 
clinician, the result of the hs-cTnI test was nested and never revealed to either patient or their 
supervising clinical team, regardless of whether the result was above the supplied ULN. The study is 
registered with Clinicaltrials.gov, number NCT03047785. 
Cardiac troponin I assay
The Beckman Coulter Access AccuTnI+3 assay (Beckman Coulter, Brea, CA, USA) is employed in routine 
clinical practice at our Trust and is employed in routine clinical practice at our Trust and was used to 
measure hs-cTnI concentrations in the study population. The supplied 99th percentile (ULN) is 40 ng/L, 
which is the level used in routine clinical practice at our institution.  The coefficient of variation (CV) 
of the assay is <10% at 40ng/L, the limit of quantification (LOQ 10% CV) is 20ng/L; the limit of detection 
(LOD) is 8ng/L; the limit of blank is 5ng/L. For those patients in whom troponin had not been requested 
for clinical reasons, the hs-cTnI concentration was measured for every individual using serum which 
was surplus to clinical need. An automated, bespoke system was put in place in Biochemistry to ensure 
each individual was only included once in the study. Serum was collected into serum separator tubes 
and stored at room temperature for up to 24 hours before cTnI levels were measured through the use 
of the DxI800 platform (Beckman Coulter, Brea, CA, USA). Quality control of the assay was undertaken 
on a daily basis as is routine in clinical practice.
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Data Collection
Baseline demographic data were limited to those derived from electronic request forms for blood 
tests and, for inpatients, from electronic discharge summary codes. These data, together with the 
troponin levels and other study data were collected on a bespoke database for later analysis.
Patient and public involvement
The British Cardiac Patients Association (BCPA) assisted the researchers in review of the study 
protocol, with particular reference to the lack of consent of participants. A letter of support for our 
methodology from the Chairman of the BCPA was submitted to the HRA/CAG as part of our study 
application.
Statistical Analysis
T The 99th percentile for the study population was defined using a non-parametric procedure based 
on frequency tables. Statistical analyses were performed using IBM SPSS V.22.0 (SPSS, IBM 
Corporation, Armonk, New York, USA).  We used Stata 14.0 (College Station, USA) to perform multiple 
logistic regressions to identify factors associated with elevated highly sensitive troponin above 40 
ng/L. Variables in the model included age, male sex, serum sodium, estimated glomerular filtration 
rate and location. 
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Results
A total of 20,000 consecutive patients were included in CHARIOT between 29/06/2017 to 24/08/2017. 
The median age was 61 (standard deviation 20) years and 52.9% were female, (n = 10,580).
The 99th percentile hs-cTnI concentration for the whole study population (n=20,000) was 296 ng/L, 
with 1 in 20 (5.4%; n=1080) of the patients having a hs-cTnI concentration above the supplied ULN (40 
ng/L). Once all patients who had been diagnosed with an AMI on discharge or in whom a hs-cTnI level 
had been requested on the basis of a clinical suspicion of MI had been excluded, this left 18,171 
patients in whom the 99th percentile was 189 ng/L, with 4.6% (n=836) above 40 ng/L (Figure 1). 
Baseline characteristics are shown in Table 1. 
Of the 1707 patients in whom hs-cTnI concentrations were requested by the clinical team, 73% 
(n=1246) had presented with chest pain, with arrhythmia (n=52) and suspected blackouts (n=63) the 
next most common reason for the test. 
Patient Location
Patients were stratified according to their location at the time the biochemistry test was requested. 
Specifically, the study included 9280 (51.1%) hospital outpatients in whom the observed 99th 
percentile was 65 ng/L, with hs-cTnI concentrations above the supplied ULN in 2% (n=186).   4759 
(26.2%) of the study population were patients admitted. The 99th percentile for this inpatient group 
was 563 ng/L, and the hs-cTnI concentrations were above the supplied ULN in 7.29% (n=347). 
A total of 5708 patients had their blood sampling in the emergency department (ED). Of this group, 
1551 (27.2%) had hs-cTnI concentrations requested by the ED clinicians. The 99th percentile for the 
remaining ED population (n= 3706) was 215 ng/L, with 6.07% (n=225) of these having hs-cTnI 
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concentrations above the supplied ULN. Patients managed in the resuscitation room (n=426) of the 
ED had hs-cTnI concentrations above the ULN in 19.48% (n=83). 
For patients managed in the critical care environment (3 intensive care and 2 high dependency units) 
(n= 123), 39.02% (n=48) had hs-cTnI concentrations above the ULN. 
Once all patients who had either been diagnosed with MI or hs-cTnI requested by the clinical team 
were excluded, a total of 14.16% (n=67) of all medical inpatients (excluding cardiac) had hs-cTnI 
concentrations above the supplied ULN. 20.8% of patients from the medicine for older people (MOP) 
(n= 20) also had hs-cTnI concentrations above the supplied ULN. 4.62% (n=16) of patients managed 
on the acute surgical unit had hs-cTnI above the ULN. For orthopaedic patients 5.24% (n=13) had hs-
cTnI concentrations above the ULN. In none of these patients was an acute MI suspected or diagnosed 
(Table 2; Figure 2).
Age
There was an association between increasing age and distribution of troponin concentration. 
Percentiles (25th, 50th, 75th, and 99th) and proportion of patients with hs-cTnI above the ULN according 
to age is shown in supplementary Table 1 and Figure 3.
Gender
The 99th percentiles for males and females were 373 ng/L and 236 ng/L, respectively. 6.6% (n=622) of 
male and 4.38% (n=463) of females had hs-cTnI concentrations above the ULN. Significant differences 
were seen in mean hs-cTnI levels when comparing males to females (62 vs 31 ng/L, p=0.021).
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Multivariable analysis
Once all patients who had either been diagnosed with MI or had hs-cTnI concentrations requested by 
the clinical team (n=1829) were excluded, a multivariable analysis was undertaken to assess the 
independent predictors of an individual having a hs-cTnI concentration above the supplied ULN (40 
ng/L). Advancing age (odds ratio (OR) 1.03(1.03-1.04), p<0.001), male gender (OR 1.33, (1.14-1.54), 
p<0.001) and reducing estimated glomerular filtration (OR 0.98(0.97-0.98), p<0.001) were shown to 
be independent predictors. Furthermore, when compared to the outpatient population, location in 
the ED (OR 2.79 (2.26-3.43), p<0.001), resuscitation room(OR 9.91 (7.3-13.46), p<0.001), critical care 
units (OR 36.62(23.86-56.2), p<0.001), cardiac wards (OR 9.08, (6.44-12.81), p<0.001), acute surgical 
unit (OR 2.52(1.47-4.33), p<0.001), medical wards (OR 4.74(3.45-6.50), p<0.001), MOP wards (OR 3.70 
(2.16-6.34), p<0.001) and orthopaedic wards (OR 2.24 (1.23-4.05), p=0.008) were independent 
predictors for hs-cTnI concentration above the ULN (table 3). Independent predictors for the full 
cohort (n=20,000) are shown in the Supplementary table 3.
Discussion
This study, which is to our knowledge the largest of its kind, has shown that 1 in 20  consecutive all 
comer patients at a large UK hospital have a troponin level that is greater than the  supplied 99th 
centile (ULN) for the assay. Our data also demonstrate that the 99th centile varies according to the 
clinical setting, age and gender, and location, with a range of 2% of outpatients and 39% of patients 
in critical care settings having a cTnI greater than the supplied ULN. 
These results have important clinical implications that are almost certainly relevant to the application 
of all modern hs-cTn assays. Firstly, they confirm our original hypothesis that the true 99th centile for 
a general hospital population is not consistent with the supplied ULN. Secondly, these data raise 
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important questions about the applicability of the quoted ULN as an arbiter of Type 1 AMI in patients 
who do not give a typical history consistent with this diagnosis. The previous evidence for the use of 
cTnI levels to rule out AMI is clear cut and robust (14-16, 32). The Fourth Universal Definition(3) 
recommends the diagnosis of AMI  when there is clinical evidence of acute myocardial ischaemia and 
with detection of a rise and/or fall of cTn values.  However, the utility of the supplied ULN as a “rule 
in” test for AMI in patients presenting with atypical symptoms and other comorbidities, such as in the 
context of ED or acute medicine and surgical patients, is flawed and potentially exposes such patients 
to inappropriate pharmacological and invasive treatment that has only been shown to be beneficial 
in true T1MI populations. This study highlights the importance of interpreting hs-cTnI results with 
caution in an individual patient. The risk of potential systematic misdiagnosis of AMI is particularly 
illustrated by the observed 99th centile for hs-cTnI in our subpopulations of ED (215 ng/L) and acute 
medical admissions (1459 ng/L), and that close to 40% of patients in some clinical settings have hs-
cTnI levels above the supplied ULN. It is particularly important for frontline clinical staff to understand 
that using a single cutoff of hs-cTnI to diagnose AMI may be inappropriate and that the ULN of the 
assay will depend on the clinical environment as well as clinical characteristics of patients. We would 
advocate that clinical staff are aware of the current guidelines in diagnosing AMI, which are not always 
adhered to, and also that they have a very clear indication for requesting the test.
Our analysis highlights a number of factors that are associated with “elevated” hs-cTnI results as 
judged by the supplied reference, including mode of presentation. Thus, 7.29% of all inpatients in this 
study had an “elevated” hs-cTnI concentration, including 6.07% of ED patients and 19.48% of those 
admitted to the resuscitation room.  It is more predictable that nearly 40% of patients admitted to a 
critical care setting have an elevated concentration. However, the finding that our observed 99th 
centile for hs-cTnI concentrations was 65ng/L in outpatients, and that 2% of these patients who 
attended the hospital only for a clinic appointment had a concentration above the supplied ULN, 
highlights the need for a review of quoted distribution of hs-cTn assay in a hospital setting. Further 
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research is now required to understand whether there is an association between absolute troponin 
concentration and outcome in such populations.
Other factors that were clearly associated with increasing hs-cTn concentrations were age and gender. 
Specifically, almost double the proportion of patients in the 7th decade of life have hs-cTnI 
concentrations above the ULN when compared patients in their 6th decade of life. Together with the 
tendency for higher levels in males compared to females in our study, these observations lend weight 
to the concept that there should be age- and gender-specific quoted levels for ULN. 
Strengths of this study
Previous literature in this field has confirmed the utility of the newer hs-cTn assays for early exclusion 
of AMI in a robust and safe manner (14-16, 32). However, interpretation of a single hs-cTnI 
concentration above the supplied ULN as being an indicator of AMI, and, more specifically, a T1MI, by 
front line clinicians has the potential to lead misdiagnosis and inappropriate investigations and 
treatment.  The data presented here indicate that the prevalence of troponin levels above the 
supplied ULN in an important proportion of patients in whom there is no clinical suspicion of acute MI 
should raise a cautionary note. 
The current findings also raise the important and interesting question about the potential implications 
of our observed distribution of hs-cTnI in the hospital population. Specifically, are the levels that we 
observe in these patients, for whom the suspicion of AMI is low (for example outpatients), actually 
abnormal?   Do the levels indicate myocardial injury in their own right, and, if so, are they associated 
with adverse outcome, perhaps as biomarkers for future cardiovascular risk?   There is an 
accumulating body of evidence that suggests that hs-cTn concentrations in populations of stable 
patients with chronic disease states, of both cardiac and non-cardiac origin, are indeed associated 
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with risk of cardiovascular events(33-42). Notably, in the outpatient population it has been reported 
that cTnI has indeed been shown to be associated with an increased risk of vascular events and all-
cause mortality(43, 44). It is conceivable that the “elevated” hs-cTn concentrations in a stable patient 
always indicates myocardial injury or unwellness:  the so called “never means nothing” hypothesis(45).
Implications of this study
The results of this study have significant implications for patient care. The notion of using a single 
binary value above the ULN of any assay to diagnose whether a patient has suffered an acute MI is 
flawed. This is highlighted by the observed 99th percentile in the CHARIOT study population which is 
over seven times higher than the ULN supplied by the manufacturer. Further, the observed frequency 
of hs-cTnI above the supplied ULN in our study, regardless of location, in patients in whom there was 
no clinical suspicion of acute MI or myocardial injury raises concerns about the utility of a 99th 
percentile value from a ‘healthy population’. In particular, applying this supplied 99th centile value to 
determine the management of patients who are typically older, have more comorbidities, higher 
incidence of subclinical cardiac disease and in a worse physical condition than the reference healthy 
population may be flawed. 
The results of this study should highlight to front line clinicians that whilst hs-cTnI can contribute to 
the diagnosis of AMI, this should only be when used in conjunction with other key factors such as the 
clinical history and other investigations(9, 24, 25, 29, 46-50). At present, the use of the 99th percentile 
to help rule out a diagnosis of AMI is clear and this is based on using a ‘healthy’ reference population. 
However, the use of this threshold level and its application to patients presenting to hospital to rule 
in AMI is problematic, particularly where the degree of suspicion is low and there are other factors 
that will contribute to the cTn concentration obtained in an individual. Currently, the implications of 
detecting a hs-cTnI above the supplied ULN, in terms of outcome and management, are unclear in 
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patients in whom there is low clinical suspicion of AMI. A more considered approach to application of 
cTnI concentrations would be a more tailored ULN according to the patient’s baseline characteristics 
and comorbidities. The feasibility of this approach, however, remains unanswered.  Further data 
regarding the potential association between hs-cTnI level and CV risk are required.
Limitations of this study
There are a number of limitations. Firstly, this is an observational study of a large number of 
consecutive patients. Necessarily, therefore, the level of detail with regard to management and 
diagnoses can only be obtained from the best records available for each patient, which included any 
electronic blood request or discharge summary data and formalised coding record. Secondly, this 
study has not looked at clinical outcomes since this was not part of our objective. Thirdly, in our 
analysis we have used discharge codes for diagnosis of AMI, but have not independently verified these 
final diagnoses. Finally, this study has looked at hs-cTnI concentrations in 20,000 patients based on a 
single sample for each patient, as a result this study cannot differentiate between acute and chronic 
myocardial injury. 
Conclusions
This study has shown that the 99th percentile of the hospital population is substantially higher than 
the supplied ULN used in clinical practice according to the manufacturer provided 99th centile for a 
healthy population. Furthermore, the 99th percentile for the hospital population varies depending on 
the clinical acuity, location, age and gender of the individual, but in all subgroups there is a proportion 
of the patients in whom the hs-cTnI concentrations are above the clinically applied ULN. This is the 
largest study to date to evaluate hs-cTnI levels in an unselected cohort of 20,000 consecutive patients 
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and the observations from this study highlight the need for clinicians to interpret hs-cTnI 
concentrations carefully and systematically when attempting to diagnose AMI, particularly Type 1 MI.
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Summary Box
What is already known:
 Current guidelines recommend the use of troponin assays to aid in the 
exclusion or diagnosis of acute myocardial infarction.
 Manufacturers of troponin assays provide a recommended 99th percentile for 
the assay that is based upon a few hundred healthy subjects. This is often used 
as an upper limit of normal when applied to the hospital population.
 It is known that a variety of clinical factors affect the troponin level, such as 
age and renal function, but little is known about the true distribution of the 
troponin level in an all comers hospital population.
What this study adds:
 In a hospital population of 20,000 consecutive patients 1/20 of all patients 
have a high sensitivity troponin I concentration above the manufacturer’s 
provided 99th percentile, in most of whom there was no clinical suspicion of 
acute MI.
 This highlights the importance of interpreting the troponin result in hospital 
patients according to (a) the individual patient and their clinical presentation 
and (b) the guideline recommendations for correct diagnosis of Type 1 & 2 
MI. 
 These results may help to avoid misdiagnosis and inappropriate treatment.
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Figure 1: A log distribution of high sensitivity cardiac troponin I (Hs-cTnI) concentration (1a) in the whole population (n=20,00) and (1b) in the 
final study population (n=18,171). (ULN = Manufacturer’s recommended upper limit of normal for Hs-cTnI concentration (>40 ng/L).
1a 1b
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Figure 2: Proportion of patients with high sensitivity cardiac troponin I concentration above the upper limit of normal (ULN = 40ng/L) according 
to location
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Figure 3: Upper limit of normal (ULN) high sensitivity cardiac troponin I concentration according to age
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Table 1: Baseline characteristics stratified by hs-cTnI levels (ng/L) below or above the 
ULN (Upper limit of normal = 40ng/L)
Hs-cTnI below ULN 
(n=18915)
Hs-cTnI above ULN 
(n=1085) 
P value
Age (years) 57.4 74.2 <0.001
Male Gender (%) 46.5 57.3 0.005
eGFR 79.1 59.6 <0.001
Na2+(mmol/L) 137.2 136 <0.001
Inpatients(%) 24.0 37.3 <0.001
Outpatients(%) 48.4 17.4 <0.001
Table 2: Distribution of hs-cTnI (ng/L) according to location. [ULN - Upper limit of 
normal = 40ng/L].
Location Median 
(ng/L)
Interquartile 
Range (ng/L)
Range 
(ng/L)
Proportion 
above ULN 
(%)
99th Centile 
(ng/L)
Inpatients (n=4759) 7 10 14994 7.29 (n=347) 563
Outpatients(n=9280) 5 8 3255 2.02 (n=187) 65
Emergency 
Department 
(n=3706)
7 9 6106 6.07 (n=225) 215
Resuscitation Room 
(n=426)
11 24 10979 19.48 (n=83) 1839
Critical Care (n=123) 25 115 13086 39.02 (n=48) 12097
Cardiac (n=269) 14 28 14994 21.56 (n=58) 3967
Acute Surgical Unit 
(n=346)
6 9 2668 4.62 (n=16) 92
Medical Wards 
(n=473)
12 22 8807 14.16 (n=67) 1459
Medicine for Older 
People (n=96)
20 27 3508 20.83 (n=20) -
Orthopaedics 
(n=248)
8 9 402 5.24 (n=13) 184
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Table 3: Independent predictors of hs-cTnI levels [ULN - Upper limit of normal = 
40ng/L].
Variable Predictors of manufacturer 
troponin ULN >40 ng/L 
(n=18,171)
Predictors of non-parametric 
troponin ULN >189 ng/L 
(n=18,171)
Age (per year increase) 1.03 (1.03-1.04) (p<0.001) 1.03 (1.02-1.04)  (p<0.001)
Male gender 1.33 (1.14-1.54) (p<0.001) 0.90 (0.66-123) (p=0.513)
Sodium (per unit increase) 0.99 (0.97-1.01) (p=0.336) 1.01 (0.97-1.04) (p=0.742)
eGFR (per unit increase) 0.98 (0.97-0.98) (p<0.001) 0.99 (0.98-1.00) (p=0.001)
Location vs outpatient
Emergency Department
Resuscitation Room
Critical Care
Cardiac
Acute surgical ward
Medical wards
Medicine for older people
Orthopaedics
2.79 (2.26-3.43) (p<0.001)
9.91 (7.3-13.46) (p<0.001)
36.62 (23.86-56.2) (p<0.001)
9.08 (6.44-12.81) (p<0.001)
2.52 (1.47-4.33) (p=0.001)
4.74 (3.45-6.50) (p<0.001)
3.70 (2.16-6.34) (p<0.001)
2.24 (1.23-4.05) (p=0.008)
3.46 (2.14-5.61) (p<0.001)
13.79(7.67-24.77)(p<0.001)
99.27 (55.51-177.54) (p<0.001)
14.91 (7.91-28.11) (p<0.001)
0.98 (0.13-7.21) (p=0.982)
5.80 (2.95-11.42) (p<0.001)
9.60 (4.00-23.00) (p<0.001)
2.15 (0.51-9.14) (p=0.298)
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Supplementary Table 1: hs-cTnI (ng/L) concentration and age
CentileCohort Age group (n)
Centile 25 Centile 50 Centile 75 Centile 99
18-29 (n=2,301) 0 3 6 56.94
30-39 (n=2,046) 1 4 7 52
40-49 (n=2,127) 1 4 8 89.88
50-59 (n=3,079) 2 5 9 180.40
60-69 (n=3,588) 3 6 11 186.55
Full cohort 
(n=20,000)
>69 (n=6,879) 6 11 20 752.60
Supplementary Table 2: hs-cTnI (ng/L) concentration and age with troponin requested and 
confirmed MI excluded
CentileCohort Age group (n)
Centile 25 Centile 50 Centile 75 Centile 99
18-29 (n=2,050) 0 3 6 55.47
30-39 (n=1,849) 1 4 7 43
40-49 (n=1,898) 1 4 8 69.01
50-59 (n=2,784) 2 5 9 72.60
60-69 (n=3,322) 3 6 11 130
Sample excluding 
MI (n=18,171)
>69 (n=6268) 6 11 19 486.34
Supplementary Table 3
Variable Predictors of manufacturer 
troponin ULN >40 ng/L 
(n=20,000)
Predictors of non-parametric 
troponin ULN >296 ng/L 
(n=20,000)
Age (per year increase) 1.03 (1.03-1.04) (p<0.001) 1.03 (1.02-1.04)  (p<0.001)
Male gender 1.38 (1.21-1.58) (p<0.001) 1.00 (0.75-1.34) (p=0.998)
Sodium (per unit increase) 0.99 (0.98-1.01) (p=0.538) 1.01 (0.97-1.05) (p=0.638)
eGFR (per unit increase) 0.979 (0.976-0.982) (p<0.001) 0.99 (0.99-1.00) (p=0.002)
Location vs outpatient
Emergency Department
Resuscitation Room
Critical Care
Cardiac
Acute surgical ward
Medical wards
Medicine for older people
Orthopaedics
3.47 (2.88-4.19) (p<0.001)
11.84 (9.09-15.41) (p<0.001)
44.02 (29.81-65.01) (p<0.001)
12.48 (9.28-16.77) (p<0.001)
2.62 (1.55-4.43) (p<0.001)
4.85 (3.57-6.60) (p<0.001)
3.83 (2.24-6.55) (p<0.001)
2.22 (1.23-4.02) (p=0.008)
7.46 (4.22-13.19) (p<0.001)
30.59(16.27-57.54)(p<0.001)
190.86 (99.59-365.76) (p<0.001)
31.30 (15.86-61.78) (p<0.001)
1.87 (0.25-14.26) (p=0.544)
8.86 (3.92-20.05) (p<0.001)
14.54 (5.08-41.56) (p<0.001)
2.15 (0.28-16.42) (p=0.460)
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Abstract
Objective
Currently Cclinicians use the cardiac troponin (cTn) assay to help determine if a patient has suffered 
aaid in the diagnosis of an acute myocardial infarction (AMI). Abnormal cTn levels are predetermined 
by the assay manufacturer. This abnormal level, which is also known as Each manufacturer provides 
the 99th percentile for or upper limit of normal (ULN), is traditionally based on cTn levels in 300 healthy 
males and 300 healthy femalesa group of healthy individuals, and this level is taken as the upper limit 
of normal (ULN). The objective of this study was to determine what is the distribution, and specifically 
the true 99th percentile, for the whole hospital population, when using the cTn assay currently in 
useemployed routinely at our institution. To define the 99th percentile of high sensitivity cardiac 
troponin I (hs-cTnI) concentration for a hospital population.
Design
Prospective study of 20,000 consecutive patients undergoing blood sampling for any reason at a large 
teaching hospital. Hs-cTnI concentrations (Beckman Coulter Access AccuTnI+3 assay) were nested for 
analysis in all cases except those in whom the supervising physician had requested hs-cTnI for clinical 
reasons.
Setting
University Hospital Southampton NHS Trust (UHS).
Participants
20,000 consecutive individuals, inpatient or outpatient, undergoing blood tests at UHS for any clinical 
reason. Hs-cTnI concentrations (Beckman Coulter Access AccuTnI+3 assay) were nested for analysis in 
all cases except those in whom the supervising physician had requested hs-cTnI  for clinical reasons. 
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Main outcome measures
Distribution of hs-cTnI concentrations of all study patients, and specifically the 99th percentile.
Results
The 99th percentile of hs-cTnI for the whole population (n=20,000) was 296 ng/L, compared to a 
manufacturer quoted 99th percentile of 40 ng/L (currently used clinically as the “upper limit of 
normal”, ULN). In 1 in 20 (5.4%, n=1080) of the total population hs-cTnI concentrations were above 
40 ng/L. After exclusion of individuals diagnosed with an acute myocardial infarction (AMI) (n=122), 
or those in whom troponin was requested (n=1707), the 99th percentile of for the remainder 
(n=18,171) was 189 ng/L. The 99th percentile for inpatients (n=4759) and outpatients (n=9280) was 
563 ng/L and 65 ng/L, respectively. Patients from the emergency department (n=3706) had a 99th 
percentile of 215 ng/L, with 6.1% (n=491225) above the quoted ULN. 39.02% (n=48) of all individuals 
from the critical care units (n=123) and 15.714.16% (n=8767) of all medical inpatients had a hs-cTnI 
concentration above the quoted ULN. 
Conclusions
In 20,000 consecutive patients undergoing a blood test for any r ason at this hospital 1 in 20 have a 
hs-cTnI above the supplied ULN. These data highlight the need for clinical staff to interpret hs-cTnI 
concentrations carefully, particularly when applying the manufacturer’s supplied ULN to diagnose 
AMI. The sole use of hs-cTnI to diagnose AMI in any patient without a typical history may be 
flawedcouldan lead to misdiagnosis in the absence of an appropriate clinical presentation.
.
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Introduction
The use of increasingly sensitive troponin assays for the exclusion or diagnosis of acute myocardial 
infarction (AMI) has become universal. The diagnosis of AMI is now defined by a rise and/or fall ofin 
cardiac troponin (cTn) concentrations, now the gold standard biomarker(1), with at least one value 
above the 99th percentile derived from a reference population of healthy individuals in the context of 
associated with an appropriate clinical context, which includes the presence of clinical 
ischaemiapresentation(2, 3) (3-5). 
Under most circumstances, the troponin assay is used requested by the front line clinician clinical staff 
to determine whether or not the a patient is experiencing a Type 1 myocardial infarction (T1MI), which 
is due to coronary plaque rupture or erosion, since robust evidence has demonstrated symptomatic 
and prognostic benefit from the application of early pharmacological and interventional treatment 
strategies in such patients. However, particularly with the advent of newer assays, this strategy has 2 
potential flawsissueschallenges.
Firstly, elevations inelevated  cTn concentrations, particularly in patients not presenting with a typical 
history of cardiac pain, are often due to myocardial injury or Type 2 myocardial infarction (T2MI)(6, 
7), which is secondary to ischaemia due to either increased oxygen demand or decreased supply rather 
than a plaque erosion event (8-10). Not only is Tthis is not well recognized when the troponin test is 
requested, or the result interpreted, but and is especially important because the majority of patients 
with T2MI have never not been shown to benefit from the same aggressive pharmacotherapy and 
invasive investigation and treatment that is offered as standard in cases of T1MI(11), with some 
exceptions including spontaneous coronary dissection, coronary embolism and coronary spasm. (10, 
12). In fact, such misdiagnosis misinterpretation may lead to inappropriate management, including 
prolonged antiplatelet therapy and invasive coronary angiography, +/- with or without 
revascularization. with the longer term risks that this entails, with the exception of some categories 
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of Type 2 MI. It should be noted,Whilst in some aetiologies of however, that in some T2MI with 
coronary aetiologies such as spontaneous coronary dissection, coronary embolism and coronary 
spasm., coronary angiography and further imaging may be useful, in the majority it may not be (10, 
12) (Baron AM J Med/ Chapman circulation). 
Secondly, the assay-specific manufacturer’s 99th centile (ULN) is generally applied as a binary “rule in” 
or “rule out” threshold for AMI. Whilst recent trial data confirm the veracity of the use of early cTn 
concentrations to confidently exclude the diagnosis of AMI (13-16), the assumption that a 
concentration above that level implies AMI (and in particular a T1MI) is often inappropriate. Both of 
these potential flaws issues in our clinical practice may be compounded in clinical practice by the 
increasing sensitivity of the available assays, particularly with the introduction of hs-cTn assays that 
are able to detect troponin at much lower concentrations than previously assays (5). Consquently, 
nNew highly sensitive cardiac troponin (hs-cTn) assays (17-21) allow for rapid exclusion of AMI, in 
order to enableand thereby facilitate the early discharge of patients from hospital. Furthermore, 
modern hs-cTn assays can detect troponin in more than 50% of the general population, with some 
assays able to detect troponin in everyone(22). The appropriate interpretation of the “elevated” hs-
cTn, particularly in relation to the diagnosis of T1MI, is therefore dependent upon a clinical 
presentation consistent with this diagnosis, and in particular, a history of cardiac-sounding chest pain, 
according to the guidelines. Currently, Tthe International Federation of Clinical Chemistry and 
Laboratory Medicine Task Force on Clinical Applications of Bio-Markers (IFCC TF-CB) currently 
recommends that the 99th percentile for any assay can be calculated using  300 ‘healthy’ men and 300 
‘healthy’ women(23). Given the number of factors that are well known to affect an individual’s 
troponin and therefore the ULN(23), including age(24), gender(25), glomerular filtration rate(26), left 
ventricular function(27), and the presence of significant inflammatory conditions (28), the 
appropriateness  of the clinically applied concept of an ULN for the trop hs-cTn assay requires closer 
scrutiny, particularly when this binary cut off levelit was derived from a limited number of healthy 
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individuals. Importantly, the approaches to determining the 99th percentile are highlyalso variable , 
with the more strict criteria used in determining healthy individuals to result in lower 99th percentile 
values(29-31).
The aims of this study were to determine (a) the true distribution of hs-cTnI concentration in an 
unselected all comer hospital population, both inpatient and outpatient, and (b) the 99th percentile 
for this population using 20,000 consecutive patients. Our hypothesis was that the true distribution 
of hs-cTnI in this population would differ from the manufacturer’s supplied ULN for this assay, thereby 
highlighting the potential for misinterpretation of a value above this level in routine clinical practice, 
particularly calling into question the validity of applying the latter as the binary arbiter of the diagnosis 
of AMI, especially T1MI, in clinical practice. 
Methods
Study population
This was a prospective, observational study that included 20,000 consecutive patients aged at least 
18 years who were undergoingin whom a biochemistry blood investigations was requested for clinical 
reasons determined by their supervising physician at our institution, a large University teaching 
hospital in the United Kingdom. Patients were included regardless of the setting in which the blood 
test was takenrequested, so that the study population included outpatients and inpatients, 
emergency department attendees, elective and emergency admissions, and every specialty within the 
hospital. For each patient included in the study, only one troponin assay measurement was performed 
on the first biochemistry blood sample that became available during the study period. That individual 
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was then excluded from further sampling, in order that a consecutive series of 20,000 different 
patients were sampledincluded. For some of the study analysis, pPatients who were discharged from 
hospital with a diagnosis of AMI or in whom a hs-cTnI level was requestedwho had been suspected of 
AMI by the clinical team, which hadwas been determined through a review of the electronic blood 
request forms submitted to the biochemistry department and via electronic discharge summaries,  
had been were excluded. leaving a final study population of 18,171 individuals.  A flow diagram of this 
is shown in figure 1. 
Ethics & Regulatory Approval
This research project was undertaken according to the principles of Good Clinical Practice and the 
Declaration of Helsinki.  The study was approved by the local ethical committee who then referred it 
to the Health Research Authority (HRA) UK and its independent Confidentiality Advisory Group (CAG) 
for further approval (Rec reference: 17/SC/0042, IRAS project ID: 215262). The latter CAG approval 
was required based upon 2 unusual aspects of the methodology. Firstly, the method did not require 
knowledge or consent from patients that an extra blood assay was being performed. Secondly, for all 
patients in our study, apart from those in whom a hs-cTnI was requested as part of their routine clinical 
care by their supervising clinician, the result of the hs-cTnI test was nested and never revealed to 
either patient or their supervising clinical team, regardless of whether the result was above the 
manufacturer’s supplied ULN. The trialstudy is registered with Clinicaltrials.gov, number 
NCT03047785. 
Cardiac troponin I assay
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The Beckman Coulter Access AccuTnI+3 assay (Beckman Coulter, Brea, CA, USA) is employed in routine 
clinical practice at our Trust and is employed in routine clinical practice at our Trust and was used to 
measure hs-cTnI concentrations in the study population. The manufacturer recommended supplied 
99th percentile (ULN) is 40 ng/L, which is the level used in routine clinical practice at our institution.  
The coefficient of variation (CV) of the assay is <10% at 40ng/L, the limit of quantification (LOQ 10% 
CV) is 20ng/L; the limit of detection (LOD) is 8ng/L; the limit of blank is 5ng/L. For those patients in 
whom troponin had not been requested for clinical reasons, the hs-cTnI concentration was measured 
for every individual using serum which was surplus to clinical need. An automated, bespoke system 
was put in place in Biochemistry to ensure each individual was only included once in the study. Serum 
was collected into serum separator tubes and stored at room temperature for up to 24 hours before 
cTnI levels were measured through the use of the DxI800 platform (Beckman Coulter, Brea, CA, USA). 
Quality control of the assay was undertaken on a daily basis as is routine in clinical practice.
Data Collection
Baseline demographic data were limited to those derived from electronic request forms for blood 
tests and, for in patients, from electronic discharge summary codes. These data, together with the 
troponin levels and other study data were collected on a bespoke database for later analysis.
Patient and public involvement
The British Cardiac Patients Association (BCPA) assisted the researchers in review of the study 
protocol, with particular reference to the lack of consent of participants. A letter of support for our 
methodology from the Chairman of the BCPA was submitted to the HRA/CAG as part of our study 
application.
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Statistical Analysis
Descriptive statistical methods were used Tto define Tthe 99th percentile for the study population was 
defined using a non-parametric procedure based on frequency tables. Statistical analyses were 
performed using IBM SPSS V.22.0 (SPSS, IBM Corporation, Armonk, New York, USA).  We used Stata 
14.0 (College Station, USA) to perform multiple logistic regressions to identify factors associated with 
elevated highly sensitive troponin above 40 ng/L. Variables in the model included age, male sex, serum 
sodium, estimated glomerular filtration rate and location. 
Results
A total of 20,000 consecutive patients were included in CHARIOT betweenfrom 29/06/2017 to 
24/08/2017. The median age was 61 (standard deviation of 20) years and 52.9% were female, (n = 
10,580).
The 99th percentile hs-cTnI concentration for the whole study population (n=20,000) was 296 ng/L, 
with 1 in 20 (5.4%; n=1080) of the patients having a hs-cTnI concentration above the manufacturer’s 
supplied ULN (40 ng/L). Once all patients who had been diagnosed with an AMI on discharge or in 
whom a troponin levelhs-cTnI had been requested on the basis of a clinical suspicion of  MI had been 
excluded, this left a group of 18,171 patients in whom  the 99th percentile  was 1899 ng/L, with 4.6% 
(n=836) above 40 ng/L (Figure 12). Baseline characteristics whether hs-cTnI concentrations were 
below or above the ULN are shown in table 1. 
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Of the 1707 patients who hadin whom hs-cTnI concentrations were requested by the clinical team, 
73% (n=1246) had presented with chest pain, bothwith arrhythmia (n=52) and suspected cardiac 
syncope blackouts(n=63) were the next most common reason for referralthe test. 
Patient Location
Patients were stratified according to their location at the time the biochemistry test was requested. 
Specifically, the study included 9280 (51.1%) hospital outpatients in whom the observed 99th 
percentile was 65 ng/L, with hs-cTnI concentrations above the manufacturer’s supplied ULN in 2% 
(n=186).   4759 (26.2%) of the study population were patients admitted. The 99th percentile for this 
inpatient group was 563 ng/L, and the hs-cTnI concentrations were above the manufacturer’s 
quotedsupplied ULN in 7.293% (n=1326347) of these. 
A total of 5708 patients had their blood sampling sampling taken in the emergency department (ED). 
Of this group, 1551 (27.2%) had hs-cTnI concentrations requested by the ED clinicians. Once patients 
who had been diagnosed with MI or had hs-cTnI concentrations requested by the ED clinicians Tthe 
99th percentile for the remaining ED population (n= 3706) was 215 ng/L,. This population did not 
include patients who had blood sampling undertaken on the resuscitation room.with 6.071% (n=2256) 
of ED patients hadthese having hs-cTnI concentrations above the manufacturer’s supplied ULN. 
Patients managed in the resuscitation room (n=426) of the ED had hs-cTnI concentrations above the 
ULN in 19.485% (n=83). 
For patients managed in the critical care environment (3 intensive care and 2 high dependency units) 
in the centre (n= 123), 39.02% (n=48) had hs-cTnI concentrations above the ULN. 
Page 43 of 56
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
REVISED MANUSCRIPT
Mariathas et al
The CHARIOT Study
July December ‘18
13
Once all patients who had either been diagnosed with MI or hs-cTnI requested by the clinical team 
were excluded, a total of 15.714.16% (n=6787) of all medical inpatients (excluding cardiac) had hs-
cTnI concentrations above the manufacturer’s supplied ULN. 20.8% of patients from the medicine for 
older people (MOP) (n= 20) also had hs-cTnI concentrations above the manufacturer’s supplied ULN. 
4.62% (n=16) of patients managed on the acute surgical unit had hs-cTnI above the ULN. For 
orthopaedic patients 4.85.24% (n=132) had hs-cTnI concentrations above the ULN. In none of these 
patients was an acute MI suspected or diagnosed (Table 2; Figure 2).
The distribution of hs-cTnI concentrations for each location is shown in figure 3table 21, with the 
proportion of patients with a hs-cTnI above the ULN displayed in figure 2.
Age
There was an association between increasing age and distribution of troponin concentration. 
Percentiles (25th,50th,75th, and 99th) and proportion of patients with hs-cTnI above the ULN according 
to age is shown in supplementary Ttable 1 and Ffigure  43.
Gender
The 99th percentiles for males and females was were 373 ng/L and 236 ng/L respectively. 6.6% (n=622) 
of male and 4.384% (n=4636) of females had hs-cTnI concentrations above the ULN. Significant 
differences were seen in mean hs-cTnI levels when comparing males to females (62 vs 31 ng/L, 
p=0.021).
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Multivariate Multivariable analysis
Once all patients who had either been diagnosed with MI or had hs-cTnI concentrations requested by 
the clinical team (n=1829) were excluded, A a multivariablete analysis was undertaken to assess the 
independent predictors of an individual having a hs-cTnI concentration above the manufacturer’s 
recommended supplied ULN (40 ng/L). Advancing age (odds ratio (OR) 1.036(1.031-1.041), p<0.001), 
male gender (OR 1.33449, (1.14253-1.54676), p<0.001) and reducing estimated glomerular filtration 
(OR 0.97798(0.974-0.980), p<0.001) were shown to be independent predictors. Furthermore, when 
compared to the outpatient population, patients who were fromlocation in the ED (OR 3.4512.79 
(2.860-4.1652.26-3.43), p<0.001), resuscitation room(OR 11.8159.91 (9.062-15.4037.3-13.46), 
p<0.001), critical care units (OR 16.60136.62(9.252-29.78423.86-56.2), p<0.001), cardiac wards (OR 
18.3899.08, (14.036-24.0926.44-12.81), p<0.001), acute surgical unit (OR 2.6222.52(1.549-4.4391.47-
4.33), p<0.001), medical wards (OR 5.0084.74(3.693-6.7923.45-6.50), p<0.001), MOP wards (OR 
3.6643.70 (2.135-6.28816-6.34), p<0.001) and orthopaedic wards (OR 2.24 5(1.24023-4.06405), 
p=0.008) were found to be independent predictors of an individual having afor hs-cTnI concentration 
above the ULN (Figure 5table 3). Independent predictors of an individual having a hs-cTnI 
concentration above the 99th centile for this population (hs-cTnI level of 189 (ng/L) ) is also shown in 
table 3. Independent predictors for the full cohort (n=20,000) are shown in the Supplementary table 
3.
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Discussion
This study, which is to our knowledge the largest of its kind, has shown that 1 in 20 of consecutive all 
comer patients at a large UK University hospital have a troponin level that is greater than the  
manufacturer’s supplied 99th centile (ULN) for the assay. These Our data also demonstrate that the 
99th centile varies according to the clinical setting, age and gender, and location with a range of 2% of 
outpatients and 39% of patients in critical care settings having a cTnI greater than the manufacturer’s 
supplied ULN depending upon their location and status. 
These results have important clinical implications that are almost certainly relevant to the application 
of all modern hs-cTn assays. Firstly, they confirm our original hypothesis that the true 99th centile for 
a general hospital population is not consistent with the manufacturer’s quotedsupplied ULN. 
Secondly, these data raise important questions about the appropriate applicability of the quoted ULN 
as an sole an arbiter of Type 1 AMI in patients who do not give a typical history consistent with this 
diagnosis. The previous evidence for the use of cTnI levels to rule out AMI is clear cut and 
justifiedrobust (14-16, 32)(10-12, 24). The Ffourth Uuniversal Ddefinition(3) recommends the 
diagnosis of AMI to be diagnosed when there is clinical evidence of acute myocardial ischaemia and 
with detection of a rise and/or fall of cTn values.  SpecificallyHowever, the utility of the manufacturer’s 
supplied ULN as a “rule in” test for AMI in patients presenting with atypical symptoms and other 
comorbidities, such as in the context of ED or acute medicine and surgical patients, is flawed and 
potentially exposes such patients to inappropriate pharmacological and invasive treatment that has 
only been shown to be beneficial in true T1MI populations. Although this management strategy is not 
recommended as per the Fourth Universal Definition(3), tThis study highlights the importance of 
interpreting hs-cTnI results with caution in an individual patientpitfalls of using this strategy. This The 
risk of potential systematic misdiagnosis of AMI is particularly highlighted illustrated by the observed 
99th centile for hs-cTnI in our subpopulations of ED (215 ng/L) and acute medical admissions (1432 
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1459 ng/L), and that close to 40% of patients in some clinical settings have hs-cTnI levels above the 
manufacturers supplied ULN. It is particularly important for frontline clinical staff to grasp and 
demonstratesunderstand that using a single cutoff of hs-cTnI to diagnose AMI may beis inappropriate 
and that the ULN of the assay will depend on the clinical environment as well as clinical characteristics 
of patients. that all We would advocate that clinical staff should be are aware of the current guidelines 
in diagnosing AMI, which are often not always adhered to, and also that they have a very clear 
indication for requesting the test.
Our analysis highlights a number of factors that are associated with “elevated” hs-cTnI results as 
judged by the manufacturer’s supplied reference, including mode of presentation. Thus, 7.329% of all 
inpatients in this study had an “elevated” hs-cTnI concentration, including 6.107% of ED patients and 
19.548% of those admitted to the resuscitation room.  It is more predictable that nearly 40% of 
patients admitted to a critical care setting have an elevated concentration. However, the finding that 
our observed 99th centile for hs-cTnI concentrations was 65ng/L in outpatients, and that 2% of these 
patients who attended the hospital only for a clinic appointment had a concentration above the 
manufacturer’s supplied ULN, highlights the need for a review of quoted distribution of the hs-cTn 
assay in a hospital setting and its quoted distribution is used in a hospital setting. Further research is 
now required to understand whether there is an association between absolute troponin 
concentration and outcome in such populations.
Other factors that were clearly associated with increasing hs-cTn concentrations were age and gender. 
Specifically, almost double the proportion of patients in the 7th decade of life have hs-cTnI 
concentrations above the ULN when compared patients in their 6th decade of life. Together with the 
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tendency for higher levels in males compared to females in our study, these observations lends weight 
to the concept that there should be age- and gender-specific quoted levels for ULN. 
Strengths of this study
Previous literature in this field has confirmed the utility of the newer hs-cTn assays for early exclusion 
of AMI in a robust and safe manner (14-16, 32). However, interpretation of a the assumption that aif 
it is assumed by clinicians that a single hs-cTnI concentration that is elevated above the manufacturer’s 
supplied ULN is as being an indicator of AMI, and, more specifically, a T1MI, is called into question by 
our findings by front line clinicians has the potential is likely to lead misdiagnosis and inappropriate 
investigations and treatment.  The data presented here indicate thatCertainly, the prevalence of 
troponin levels above the manufacturer’s supplied ULN in an important proportion of patients in 
whom there is no clinical suspicion of acute MI should raise a cautionary note. for front line clinical 
staff who request the troponin test in patients in whom the presentation is uncharacteristic of AMI.
The current findings also raise the important and interesting question about the potential implications 
of our observed distribution of hs-cTnI in the hospital population. Specifically, are the levels that we 
observe in these patients, for whom the suspicion of AMI is low (for example outpatients), actually 
abnormal?   Do the levels indicate myocardial injury in their own right, and, if so, are they associated 
with adverse outcome, perhaps as as such, carry importance as biomarkers for future cardiovascular 
risk?   There is an accumulating body of evidence that suggests that hs-cTn concentrations in 
populations of stable patients with chronic disease states, of both cardiac and non-cardiac origin, are 
indeed associated with cardiovascular risk of cardiovascular events(33-42). It should be noted 
thatNotably, in the outpatient population it has been shownreported that cTnI has indeed been shown 
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to be associated with an increased risk of vascular events and all- cause mortality(43, 44) (Everett). 
Furthermore, patients with merely detectable hs-cTn levels have been shown to have a similar risk of 
adverse events as those who have presented with an ACS(44) (Than MP clinical chemistry 2018). How 
this adverse event risk can be modified is yet to be determined.  It is conceivable that the “elevated” 
hs-cTn concentrations in a stable patient, always indicates myocardial injury or unwellness:  the so 
called “never means nothing” hypothesis(45).
Implications of this study
The results of this study have significant implications for patient care. The notion of using a single 
binary value above the ULN of any assay to diagnose whether a patient has suffered an acute MI is 
flawed. This is reflected highlighted in by the observed 99th percentile ULN observed in theis CHARIOT 
study population which is over seven times higher than the currently recommended ULN by the 
manufacturersupplied by the manufacturer. Further, the observed frequency of In addition, the fact 
that only 1 in 7 of all patients with a hs-cTnI above the supplied ULN in our study, regardless of 
location, in patients in whom there was no clinical suspicion of acute MI or myocardial injury were 
diagnosed with MI also raises concerns over about the use utility of a 99th percentile value from a 
‘healthy population’. and, inIn particular, applying this supplied 99th centile value to direct determine 
the management of patients who are typically older, have more comorbidities, higher incidence of 
subclinical cardiac disease and in a worse physical condition than the reference healthy population 
may be flawed. 
The results of this study should highlight to front line clinicians that whilst hs-cTnI can contribute to 
the diagnosis of AMI, this should only be when used in conjunction with other key factors such as the 
clinical history and other investigations(9, 24, 25, 29, 46-50). At present, the use of the 99th percentile 
to help rule out a diagnosis of AMI is clear and this is based on using a ‘healthy’ reference population. 
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However, the use of this threshold level and its applyingication to patients presenting to hospital to 
rule in AMI can lead to issuesis problematic, particularly where the degree of suspicion of index is low 
and there are other conditionsfactors that will contribute to an individual’sthe cTn concentration 
obtained in an individual. Currently, the implications of detecting a hs-cTnI above the supplied ULN, 
in terms of outcome and management, are unclear in patients in whom there is low clinical suspicion 
of AMI.where acute or chronic myocardial injury is diagnosed in the absence of AMI, as shown in this 
study, the optimal treatment strategy for this cohort of patients is unclear. A more considered 
approach to application usingof cTnI concentrations would be a more tailored ULN according to the 
patient’s baseline characterisitics and comorbidities. However, Tthe feasibility of this approach, 
however,  remains unanswered. .  Further data regarding the potential association between hs-cTnI 
level and CV risk are required. 
Limitations of this study
There are a number ofsome limitations of this study. Firstly, this is an observational study of a large 
number of consecutive patients. Necessarily, therefore, the level of detail with regard to management 
and diagnoses can only be obtained from the best records available for each patient, which includeds 
any electronic blood request or discharge summary data and otherwise the formalised coding record. 
Secondly, this study has not looked at clinical outcomes since this was not part of our objective. 
Thirdly, in our analysis we have used discharge codes for diagnosis of AMI,  but have not independently 
verified these final diagnoses. Finally, this study has looked at hs-cTnI concentrations in 20,000 
patients based on a single sample for each patient, as a result this study cannot differentiate between 
acute and chronic myocardial injury. 
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Conclusions
This study has shown that the 99th percentile of the hospital population is substantially higher than 
the supplied ULN used in clinical practice according to the manufacturer provided 99th centile for a 
healthy population. according to the manufacturer’s recommendation. Furthermore, the 99th 
percentile for the hospital population varies greatly depending on the clinical acuity, location, age and 
gender of the individual, but in all subgroups there is a proportion of the patients in whom the hs-cTnI 
concentrations are above the clinically applied ULN. This is the largest study to date to evaluate hs-
cTnI levels in an unselected cohort of 20,000 consecutive patients and the observations from this study 
highlight the need for clinicians to interpret hs-cTnI concentrations carefully and systematically when 
attempting to diagnose AMI, particularly Type 1 MI.
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